Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ziprasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 0.96 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 0.96 |
| ▸ | HTR7 | P34969 | 3/20 | 0.96 |
| ▸ | HTR6 | P50406 | 2/20 | 0.96 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.96 |
| ▸ | HTR3B | O95264 | 1/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
| ▸ | PGR | P06401 | 1/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.96 |
| ▸ | GOT1 | P17174 | 1/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ziprasidone SCHEMBL930539 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL1164202 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL29594402 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL10324884 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL6061373 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL2978306 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL2978308 | 1.00 | KCNH2 (1.00) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL4914143 | 0.99 | HTR2A (0.98) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL30354044 | 0.99 | HTR2A (0.98) | KCNH2MTORRAB9AHTR2ADRD2 | |
| Ziprasidone SCHEMBL374870 | 0.99 | HTR2A (0.98) | KCNH2MTORRAB9AHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4359 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| EP-3194027-B1 | COMPOSITIONS FOR USE IN TREATING PSYCHOTIC DISORDERS | SOUND PHARMACEUTICALS INCORPORATED (US) | 2026-02-11 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| CN-120121734-A | Method for detecting residual solvent benzene in ziprasidone hydrochloride bulk drug | 重庆锐恩医药有限公司 | 2025-06-10 | — | — | CN | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | claimed |
| CN-119804720-A | Liquid chromatography tandem mass spectrometry detection method of psychotropic drugs based on magnetic solid phase extraction | 天津智谱仪器有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-20250057809-A1 | COMPOSITIONS AND METHODS FOR TREATING INDUCED DISORDERS FOLLOWING NON-HEMORRHAGIC CLOSED HEAD INJURY | BOULDER BIOSCIENCE LLC | 2025-02-20 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-6150366-A | CRYSTALLINE ZIPRASIDONE FREE BASE OR CRYSTALLINE ZIPRASIDONE HYDROCHLORIDE PARTICLES WITH SPECIFIC PARTICLE SIZE ARE USEFUL AS ANTIPSYCHOSIS AGENT | PFIZER INC. (US) | 2000-11-21 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| EP-1029861-A1 | Benzisothiazol-piperazinyl derivative and its use as neuroleptic | PFIZER INC. (US) | 2000-08-23 | — | — | EP | claimed |
| EP-0985414-A2 | Method of treating glaucoma and ischemic retinopathy | Pfizer Products Inc. (US) | 2000-03-15 | — | — | EP | claimed |
| EP-0965343-A2 | Ziprasidone formulations | Pfizer Products Inc. (US) | 1999-12-22 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-5338846-A | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt | PFIZER INC. (US) | 1994-08-16 | — | — | US | claimed |
| US-5312925-A | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride | PFIZER INC. (US) | 1994-05-17 | — | — | US | claimed |
| EP-0584903-A1 | Process for preparing aryl piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1994-03-02 | — | — | EP | claimed |